NVUS Share Price | Eledon Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Eledon Pharmaceuticals, Inc. do?

Overview: Eledon Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market cap: USD 168.27 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.09 Return on Equity: -83.68% Price to Book: 1.47Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Eledon Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Eledon Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Bollinger Bands are showing a mildly bearish trend on the weekly chart and bearish on the monthly chart. Additionally, the KST is bearish on the weekly timeframe and mildly bearish monthly. The Dow Theory confirms a mildly bearish outlook on both weekly and monthly bases. In terms of performance, Eledon has underperformed the S&P 500 across multiple periods, with a year-to-date return of -38.11% compared to the S&P 500's 12.22%, and a 5-year return of -84.09% versus the S&P 500's 96.61%. Overall, the current technical stance is bearish, indicating weakness in the stock's performance.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

493.51 k

Shareholding (Sep 2025)

FII

5.35%

Held by 37 FIIs

DII

73.93%

Held by 17 DIIs

Promoter

8.44%

How big is Eledon Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Eledon Pharmaceuticals, Inc. has a market capitalization of 168.27 million and reported net sales of 0.00 million with a net profit of -41.60 million over the last four quarters. Shareholder's funds were 118.14 million, and total assets were 229.44 million.

View full answer

What does Eledon Pharmaceuticals, Inc. do?

22-Jun-2025

Eledon Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $6 million and a market cap of $168.27 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -83.68%.

View full answer

Is Eledon Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Eledon Pharmaceuticals, Inc. is in a bearish trend, with negative indicators across multiple technical analyses and significant underperformance compared to the S&P 500.

View full answer

Compare Eledon Pharmaceuticals, Inc. with Similar Stocks

CASI Pharmaceuticals, Inc.NextCure, Inc.Lantern Pharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 165 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.02

Return on Equity

-89.81%

Price to Book

1.81

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-48.32%

6 Months

-33.85%

1 Year

-53.96%

2 Years

24.28%

3 Years

-26.62%

4 Years

-43.27%

5 Years

-85.71%

Eledon Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-244.11%

EBIT to Interest (avg)

-39.90

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

Tax Ratio

2.32%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

84.54%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.61

EV to EBIT

-0.77

EV to EBITDA

-0.77

EV to Capital Employed

-6.00

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-83.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 16 Schemes (12.28%)

Foreign Institutions

Held by 37 Foreign Institutions (5.35%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 75.06% vs -367.71% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.70",
          "val2": "-14.40",
          "chgp": "-71.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "12.30",
          "val2": "-31.30",
          "chgp": "139.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-44.90",
          "chgp": "75.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.93% vs -32.39% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.20",
          "val2": "-42.60",
          "chgp": "-64.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "30.90",
          "val2": "-76.20",
          "chgp": "140.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.20",
          "val2": "-116.50",
          "chgp": "68.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-24.70

-14.40

-71.53%

Interest

0.00

Exceptional Items

12.30

-31.30

139.30%

Consolidate Net Profit

-11.20

-44.90

75.06%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 75.06% vs -367.71% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-70.20

-42.60

-64.79%

Interest

0.00

Exceptional Items

30.90

-76.20

140.55%

Consolidate Net Profit

-36.20

-116.50

68.93%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.93% vs -32.39% in Dec 2023

All Annual Results

Company CV

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Eledon Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Eledon Pharmaceuticals, Inc.?

Watch in Real-Time

What does Eledon Pharmaceuticals, Inc. do?

Is Eledon Pharmaceuticals, Inc. technically bullish or bearish?

Compare Eledon Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Eledon Pharmaceuticals, Inc.

Company Coordinates